Literature DB >> 21295608

PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9.

Jingmin Zhou1, Xiao Yang, J Fraser Wright, Katherine A High, Linda Couto, Guang Qu.   

Abstract

Column chromatography has been described for purification of recombinant adeno-associated viral vectors (rAAV) serotypes 1, 2, 5, 6 and 8. Some of these purification processes have been used in manufacturing pre-clinical grade and clinical grade rAAV vectors. Recently, recombinant AAV9 has been reported to be highly efficient in transducing cardiac muscle in animal models. Systemic or cardiac gene delivery and other applications may require large quantities of rAAV9 vectors, thus a scalable method supporting large scale purification of rAAV9 is needed for clinical development. However, column chromatography-based purification has not been reported to date for rAAV9. This study reports a polyethylene glycol (PEG) modulated chromatography process for purification of AAV9 vectors. Inclusion of PEG in chromatography buffers modulated rAAV9 elution profiles in a manner that resulted in significantly improved resin binding capacity, vector purity and yield. PEG-modulated methods were developed and optimized for hydroxyapatite and ion exchange chromatography, and shown to result in vectors of high purity and functional activity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295608     DOI: 10.1016/j.jviromet.2011.01.013

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography.

Authors:  Martin Lock; Mauricio R Alvira; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

2.  A tribute to Dr. Serge N. Timasheff, our mentor.

Authors:  Kirk Aune; James Lee; V Prakash; Rajiv Bhat; Jose Andreu; Octavio Monasterio; Bernardo Perez-Ramirez; Keith Shearwin; Tsutomu Arakawa; John Carpenter; John Crowe; Lois Crowe; George Somero; Pete Gagnon; Marina Timasheff Charles
Journal:  Biophys Rev       Date:  2021-07-06

Review 3.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

4.  A simplified purification protocol for recombinant adeno-associated virus vectors.

Authors:  Mark Potter; Bridget Lins; Mario Mietzsch; Regine Heilbronn; Kim Van Vliet; Paul Chipman; Mavis Agbandje-McKenna; Brian D Cleaver; Nathalie Clément; Barry J Byrne; Sergei Zolotukhin
Journal:  Mol Ther Methods Clin Dev       Date:  2014-08-13       Impact factor: 6.698

Review 5.  Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.

Authors:  Weihong Qu; Mingxi Wang; Yaqing Wu; Ruian Xu
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

6.  Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9.

Authors:  Taro Tomono; Yukihiko Hirai; Hironori Okada; Yoshitaka Miyagawa; Kumi Adachi; Shuhei Sakamoto; Yasuhiro Kawano; Hideto Chono; Junichi Mineno; Akiko Ishii; Takashi Shimada; Masafumi Onodera; Akira Tamaoka; Takashi Okada
Journal:  Mol Ther Methods Clin Dev       Date:  2018-11-01       Impact factor: 6.698

7.  Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin.

Authors:  Qiang Wang; Martin Lock; Andrew J Prongay; Mauricio R Alvira; Boris Petkov; James M Wilson
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-04       Impact factor: 6.698

8.  Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes.

Authors:  Shelley A Nass; Maryellen A Mattingly; Denise A Woodcock; Brenda L Burnham; Jeffrey A Ardinger; Shayla E Osmond; Amy M Frederick; Abraham Scaria; Seng H Cheng; Catherine R O'Riordan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-12-22       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.